John Volpone, President of X4 Pharmaceuticals, Inc. (NASDAQ:XFOR), filed a Form 4 on August 13, 2026, disclosing the sale of 24,576 shares of common stock on August 12, 2026, to cover a personal income tax obligation upon settlement of a restricted stock unit award.

Key Highlights

  • Shares sold: 24,576 shares of common stock were disposed of on August 12, 2026.
  • Weighted average price: Shares were sold at a weighted average price of $4.4445, with individual transactions ranging from $4.33 to $4.55, inclusive.
  • Purpose of sale: The filing states the sale was to cover a personal income tax obligation upon settlement of a restricted stock unit award.
  • Remaining ownership: Following the transaction, Volpone beneficially owns 265,305 shares directly.
  • Restricted stock units: Of the 265,305 shares reported, 193,254 represent restricted stock units, according to the filing.

Details of John Volpone's Share Disposition at X4 Pharmaceuticals

According to the Form 4 filed with the SEC on August 13, 2026, John Volpone, serving as President of X4 Pharmaceuticals, Inc. (NASDAQ:XFOR), disposed of 24,576 shares of common stock on August 12, 2026. The filing designates the transaction with code "S" and identifies the shares as disposed of (D) through direct ownership. The stated reason for the sale, as disclosed in the filing's explanation of responses, was "sale of shares to cover personal income tax obligation upon settlement of restricted stock unit award."

The filing reports that the $4.4445 price listed is a weighted average, as the shares were sold across multiple transactions at prices ranging from $4.33 to $4.55, inclusive. The filing notes that Volpone "undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."

Following the reported transaction, Volpone directly beneficially owns 265,305 shares of common stock. The filing clarifies that of those shares, 193,254 represent restricted stock units. The Form 4 was signed by David Kirske as Attorney-In-Fact on August 13, 2026.

What Was Disclosed

John Volpone, President of X4 Pharmaceuticals, disclosed the sale of 24,576 shares at a weighted average price of $4.4445 on August 12, 2026, to satisfy a personal tax obligation tied to a restricted stock unit settlement, leaving him with 265,305 directly held shares.